EpiPen Price Figures: Mylan Accused Of Bilking Medicaid Program By Misclassifying Drug, Holding Back Rebates
October 6, 2016
Medicaid officials said drugmaker Mylan NV, which has been the focus of controversy over its EpiPen pricing policy, bilked taxpayers of a substantial sum by overcharging Medicaid for the life-saving devices.